Tag - Theralase

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Developments

Theralase enrols first patient in Phase 2 NMIBC clinical study

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) enrolled the first patient in a Phase 2 clinical study of its light activated photodynamic compounds (PDC) in patients with non-muscle invasive bladder cancer (NMIBC) who...

July 29, 2019

Developments

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence enrolling and treating...

July 24, 2019

Tag - Theralase

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase enrols first patient in Phase 2 NMIBC clinical study

Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial

General

More